RESOLVING THE LEDGER
This is one outlet's own report from STAT — the article as it was filed. Other outlets are covering the same event; open the full story to compare every source side by side.
See the full story · 1 sources
Argenx said Monday it would buy Forte Biosciences to expand its immunology pipeline, continuing the sector’s acquisition run , as even midsize companies hunt for pick-up targets.
The deal, worth $2.2 billion in cash, values Dallas-based Forte at $77 per share, a 41% premium to the biotech’s closing price on Friday.
Argenx, which has its main operations in Belgium, has become a top success story in immunology. Its drug Vyvgart, approved to treat the autoimmune diseases generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, has delivered steady sales increases as its label has been widened to cover more patients.
Continue to STAT+ to read the full story…
AIPROPX is an independent multi-source news index — we track, compare, and connect coverage from across the web into one place you won't find anywhere else.